Table 1.
Post-vaccination period (2014–17): Characteristics of unvaccinated and vaccinated women.
Table 2.
Characteristics of women in the pre-vaccination (2008–10) and post-vaccination period (2014–17).
Fig 1.
Global HR-HPV group prevalence by period of study.
HR-HPV group prevalence in post-vaccination period by vaccination status and post-vaccination biennium.
Table 3.
HPV 16/18: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.
Fig 2.
Adjusted effectiveness of HR-HPV 16/18 and 31/33/45, in vaccinated vs. unvaccinated women in the post-vaccination period (direct effectiveness), unvaccinated women in the post-vaccination period vs. women in the pre-vaccination period (indirect effectiveness), vaccinated women vs. women in the pre-vaccination period (total effectiveness), and vaccinated and unvaccinated women in the post-vaccination period vs. women in the pre-vaccination period (overall effectiveness).
Table 4.
HPV 31/33/45: Prevalence ratio employed for calculating direct, indirect, total and overall effectiveness.
Table 5.
Raw and adjusted prevalence ratios of HR-HPV genotypes different from 16/18/31/33/45, in vaccinated vs. unvaccinated women, unvaccinated women vs. pre-vaccination period, vaccinated women vs. pre-vaccination period, and post-vaccination period (vaccinated and unvaccinated women) vs. pre-vaccination period.